Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial — Stella

Home/Anti-MDA5 Positive Dermatomyositis-Associated RP-ILD/

View on ClinicalTrials.gov

Recruiting

Back to Anti-MDA5 Positive Dermatomyositis-Associated RP-ILD trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong

Key details

Phase

Early testing

Sponsor

Li Shiyue

Enrollment target

~10 participants

Started

April 2025

Primary completion

December 2026

Age range

18 Years – 75 Years

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.